Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Blog
October 31, 2026
Fenofibrate, a prescription pill for high triglycerides, slowed diabetic retinopathy in large trials, most clearly in people who already had early disease. In the LENS trial, 22.7% of people on fenofibrate developed referable retinopathy or needed eye treatment over about 4 years, versus 29.2% on placebo [1]. It did not improve vision, it is off-label for retinopathy in the US as of October 2026, and it needs kidney and liver monitoring [1,7].
This article is general education. Do not start, stop or change fenofibrate or any other medicine without the clinicians who manage your diabetes, kidneys and eyes.
Key takeaways
In this article
Call 911 for:
Go to an emergency room or eye emergency service now for sudden vision loss or a curtain or shadow across your vision.
Call your doctor the same day for:
Bleeding inside the eye needs treatment right away, whatever pills you take [10].
Fenofibrate is a fibrate, a different class from statins. It acts on a cell receptor called PPAR-alpha and is approved in the US to lower high triglycerides and, in some cases, LDL cholesterol [7]. It was studied for the eyes after large heart trials in type 2 diabetes found fewer retinal laser treatments and less retinopathy progression [1].
How it helps the retina is not settled. In FIELD, the need for laser was not related to blood lipid levels [3].
The US label notes that fenofibrate did not reduce heart disease events or deaths in two large trials of people with type 2 diabetes [7].
In ACCORD Eye, fenofibrate was added to simvastatin, not used instead of it [4]. Do not swap a statin for fenofibrate because of your eyes.
FIELD enrolled 9,795 people aged 50 to 75 with type 2 diabetes and gave fenofibrate 200 mg a day or placebo for about 5 years. First laser treatment was needed by 3.4% on fenofibrate versus 4.9% on placebo. That is a 31% lower relative risk, or 1.5 percentage points [3,11].
A smaller eye substudy of 1,012 people graded retinal photographs. Its main measure, worsening by 2 or more steps, did not differ significantly overall: 9.6% versus 12.3% [3].
The picture split by baseline eye status:
So FIELD's eye signal came mainly from less laser use and from people who already had retinopathy. Many people with diabetic macular edema (DME) now get eye injections instead, so FIELD's laser numbers do not translate directly into fewer injections.
ACCORD enrolled 10,251 people with type 2 diabetes at high heart risk. Among 1,593 people in both its eye and lipid studies, 4-year progression was 6.5% with fenofibrate 160 mg plus simvastatin. With placebo plus simvastatin, it was 10.2%. The adjusted odds ratio was 0.60 [4].
Progression meant worsening by 3 or more steps on a standard photo scale, or proliferative retinopathy needing laser or vitrectomy [4]. Moderate vision loss was not reduced: 16.0% on fenofibrate versus 15.2% on placebo [4].
The benefit did not last after the trial. In the ACCORDION follow-up, about 4 years after the trial closed, progression was 11.8% in the former fenofibrate group versus 10.2% with former placebo. The authors concluded that the fenofibrate benefit did not persist [5]. In contrast, the benefit of earlier intensive blood sugar control did persist [5].
LENS was the first large trial designed only to test fenofibrate for the eyes [2]. It enrolled 1,151 adults through Scotland's diabetic eye screening program. All had early, non-referable retinopathy or maculopathy; 26% had type 1 diabetes, and the average age was 61 [2]. Participants took fenofibrate 145 mg daily, or every other day if kidney function was reduced, or placebo [1].
Over a median of 4.0 years, results were [1]:
LENS matters because it focused on early disease and included type 1 diabetes, which earlier trials did not [1,2].
| Trial | Who and what | Main eye result | Vision |
|---|---|---|---|
| FIELD (2007) | 9,795 adults with type 2 diabetes; fenofibrate 200 mg vs placebo; about 5 years | First laser 3.4% vs 4.9%; photo worsening reduced only in those with existing retinopathy [3] | Not a main outcome |
| ACCORD Eye (2010) | 1,593 adults with type 2 diabetes and high heart risk; fenofibrate 160 mg plus simvastatin vs simvastatin alone; 4 years | Progression 6.5% vs 10.2%; benefit gone about 4 years after stopping [4,5] | No reduction in moderate vision loss [4] |
| LENS (2024) | 1,151 adults with early retinopathy, type 1 or 2; fenofibrate 145 mg vs placebo; median 4 years | Referable retinopathy or treatment 22.7% vs 29.2% [1] | No effect on acuity or quality of life [1] |
The percentages are not directly comparable. The trials used different populations, outcome definitions and background care.
In LENS, about 6 or 7 fewer people per 100 reached the main outcome over 4 years. That means roughly 16 people would need to take fenofibrate for 4 years for one to avoid it. In ACCORD Eye, it was about 27 people over 4 years. These are rough trial averages, not personal predictions [1,4].
LENS's hazard ratio of 0.73 is often reported as "27% lower risk." That is a relative figure. The absolute difference was 6.5 percentage points (29.2% minus 22.7%) [1].
For ACCORD Eye, the absolute difference was 3.7 percentage points. Its odds ratio of 0.60 is not the same as a 40-point drop [4]. For FIELD's laser outcome, the absolute reduction was 1.5 percentage points, or roughly 67 people treated for about 5 years per laser treatment avoided [3].
A 2023 Cochrane review searched studies up to February 2022, before LENS. It pooled FIELD and ACCORD, with 15,313 people with type 2 diabetes [6]. In a mixed group with and without retinopathy, fenofibrate likely made little difference to progression (risk ratio 0.86, 95% CI 0.60 to 1.25) [6].
In people who already had retinopathy, fenofibrate likely slowed progression (risk ratio 0.21, 95% CI 0.06 to 0.71), based on 208 people [6]. The review also found more serious adverse events with fenofibrate (risk ratio 1.55, 95% CI 1.05 to 2.27, high-certainty evidence). It found no evidence in type 1 diabetes at that time [6].
LENS later added type 1 data and a trial built around early retinopathy, so check whether any summary predates it [1,2].
No. As of October 2026, the US fenofibrate label we reviewed (revised July 2025) lists lipid uses only, so prescribing it to slow retinopathy is off-label. A licensed prescriber can still choose it and should monitor kidney and liver safety. It is not something to start on your own [7].
Other guidance:
The evidence fits best for adults with documented early, nonproliferative retinopathy who want to lower the chance of progression. Check your stage in our guide to the four stages of diabetic retinopathy.
In FIELD, the eye benefit did not depend on blood lipid levels, so a normal triglyceride result does not by itself rule fenofibrate out [3].
Fenofibrate does not replace treatment for established disease. If you have DME or proliferative disease, read about injections, laser and surgery and diabetic macular edema.
Fenofibrate raises blood creatinine and lowers eGFR, a blood-test estimate of kidney filtering. In studies this rise reversed within weeks of stopping. Long-term FIELD data even suggest slower kidney decline. But fenofibrate must not be used with severe kidney disease or dialysis, and kidney tests are needed before and during treatment [7,11,12].
What the studies found:
Fenofibrate is contraindicated with an eGFR below 30, including end-stage kidney disease and dialysis. With an eGFR of 30 to under 60, the label we reviewed says to start at its lower 48 mg dose [7]. Kidney function should be checked before starting and regularly after [7]. Protocol AF excluded people with an eGFR below 45 and set the dose by kidney function [9].
A 2026 expert panel said a temporary creatinine rise alone should not prompt stopping [13]. But a rise can also mean dehydration or true kidney injury, so your prescriber should check.
The most common side effects in label trials were abnormal liver tests, raised muscle enzyme (CPK) and a runny nose (rhinitis) [7]. Serious but less common risks include liver injury, muscle breakdown (rhabdomyolysis), gallstones, pancreatitis, blood clots and severe allergic or skin reactions [7].
Key interactions and cautions from the US label [7]:
In FIELD, blood clots in the lungs occurred in 1.1% on fenofibrate versus 0.7% on placebo [7]. Bring a full list of medicines and supplements to your prescriber and pharmacist.
Protocol AF (NCT04661358) is a US phase 3 trial testing whether fenofibrate prevents diabetic retinopathy from worsening. As of October 2026, ClinicalTrials.gov lists it as active and not recruiting, with 563 people enrolled. Estimated completion is December 2029, and no results have been posted [9].
Key design points from the trial record [9]:
Status may change, so check the registry for updates.
For the full prevention picture, see how to prevent diabetic vision loss. Our diabetic retinopathy guide summarizes all current treatments.
Netra Restoration Therapy (NRT) is an acupuncture and Oriental medicine program that Netra Eye Institute offers alongside care from your eye doctor. It is not a substitute for fenofibrate or any prescribed medicine, and it does not treat or reverse diabetic retinopathy. NRT has not been tested in controlled trials for diabetic retinopathy.
It should never delay eye exams, injections, laser or surgery. Tell your prescriber about every herb or supplement you take. Learn what NRT involves and what is known about its effectiveness.
No. As of October 2026, the US fenofibrate label we reviewed covers very high triglycerides and some high LDL cholesterol, not diabetic retinopathy. A doctor can still prescribe it off-label to slow retinopathy, with kidney and liver monitoring.
No. Fenofibrate is a fibrate, a separate drug class that acts on the PPAR-alpha receptor and mainly lowers triglycerides. Statins mainly lower LDL cholesterol. Taking the two together raises the risk of muscle damage, so doctors weigh the combination carefully.
In the US, fenofibrate is approved, along with diet, to lower very high triglycerides of 500 mg/dL or more. It is also approved to lower high LDL cholesterol when recommended LDL-lowering treatment is not possible. Some doctors prescribe it off-label to slow early diabetic retinopathy.
In the LENS trial, 22.7% of people on fenofibrate reached referable retinopathy or needed eye treatment over about 4 years, versus 29.2% on placebo. That is a 27% lower relative risk, or about 6 to 7 fewer people per 100. In ACCORD Eye, progression was 6.5% versus 10.2% over 4 years.
Fenofibrate raises blood creatinine and lowers eGFR, but in studies this reversed within weeks of stopping. Long-term FIELD data showed slower kidney decline. It must not be used with an eGFR below 30 or on dialysis, and lower doses are used with moderate kidney disease. Kidney tests are needed before and during treatment.
It depends on the product. Some US fenofibrate tablets can be taken at any time of day, with or without food. The Protocol AF trial gives it with food. Follow the instructions on your own prescription label or ask your pharmacist.
The most common side effects in label trials were abnormal liver tests, raised muscle enzyme levels and a runny nose. Less common but serious risks include liver injury, muscle breakdown, gallstones, pancreatitis, blood clots and severe allergic reactions. Report unexplained muscle pain, yellow skin or dark urine promptly.
LENS included people with type 1 diabetes, who made up 26% of participants, and its main result applied to the whole mixed group. The US Protocol AF trial also includes type 1 diabetes. The UK NICE recommendation covers type 2 diabetes only, so use in type 1 diabetes is a case-by-case decision.
Sources checked October 31, 2026.
This article provides general education and does not replace an individual eye examination, diagnosis or treatment plan. If you have diabetic retinopathy and notice sudden vision loss, a curtain, or a new shower of floaters or flashes, get same-day eye care whether or not you take fenofibrate.
